Home / Companies / Karuna Therapeutics, Inc. / 12 Mar 2024
Karuna Therapeutics, Inc.: meeting of 12 Mar 2024
Votes reported on Form N-PX, item by item
451 Form N-PX filers reported votes at the Karuna Therapeutics, Inc. meeting of 12 Mar 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
647 vote records from 439 filers. 128 of the 424 filers that marked the item either way voted against management. 15 filers reported this item without a management mark.
2 filers reported share counts too large to be the holding described. Those figures are left out of the share split below; the counts of filers include them. How that is decided
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
257 vote records from 144 filers. 0 of the 144 filers that marked the item either way voted against management.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
348 vote records from 170 filers. 26 of the 170 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Say-on-pay |
|---|---|
| Vanguard | For |
| BlackRock and iShares | For |
| Fidelity | For |
| Dimensional | Against * |
| State Street and SPDR | For |
| American Century | For |
| Franklin Templeton | For |
| Invesco | For |
| Equitable | Against * |
| Charles Schwab | Against * |
| Nuveen and TIAA | Against * |
| ProShares and ProFunds | For |
| John Hancock and Manulife | Against * |
| Morgan Stanley, Eaton Vance and Calvert | For |
| J.P. Morgan | For |
| Goldman Sachs | For |
| PGIM and Prudential | Against * |
| Jackson National funds | Against * |
| Northern Trust and FlexShares | For |
| SEI | Against * |
| T. Rowe Price | Against * |
| Lincoln Financial | For |
| Voya | Abstain or withhold * |
| First Trust | For |
| Nationwide | For |
| Victory Capital | For |
| Brighthouse Funds | For |
| Guggenheim and Rydex | For |
| Columbia Threadneedle | For |
| BNY Mellon | For |
| Principal | For |
| Capital Group and American Funds | Against * |
| Pacific Life funds | For |
| Transamerica | Against * |
| AllianceBernstein | Against * |
| Hartford Funds | For |
| DWS | For |
| PIMCO | For |
| Allspring | For |
| MassMutual | Against * |
| Virtus | For |
| Janus Henderson | For |
| Neuberger Berman | Against * |
| Natixis and Loomis Sayles | Against * |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Karuna Therapeutics, Inc. meeting?
451 Form N-PX filers reported votes at the meeting of 12 Mar 2024. On say-on-pay, 128 of 424 voted against management (30.2%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Karuna Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Karuna Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Karuna Therapeutics, Inc. with a meeting date within three days of 12 Mar 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.